glp-1 obesity drug news today october 16 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care Outlook for Obesity in 2026:

The availability of semaglutide in different formulations, such as injections and oral tablets, provides patients with options that cater to their preferences

Last month, Lilly announced that orforglipron, an orally available GLP-1 treatment, significantly lowered blood glucose levels in patients with type 2 diabetes

doi: 10.2741/482 68 de la MonteSMTongM

This interesting finding, occurring without weight loss, is consistent with preclinical and clinical studies showing weight-independent effects of GLP-1R agonism on liver steatosis 51,52,53

Mechanism: This effect is mediated by the activation of the vagus nerve and direct effects on gastric smooth muscle (Zheng et al., 2024)